

1 **Full Title:** Radiomic Profiling of Chest CT in a Cohort of Sarcoidosis Cases

2

3 **Authors:** Nichole E Carlson, PhD<sup>1</sup>, William Lippitt, MS, PhD<sup>1</sup>, Sarah M Ryan, PhD<sup>1</sup>,  
4 Margaret Mroz, MS<sup>2</sup>, Briana Barkes, MPH<sup>2</sup>, Shu-Yi Liao, MD, MPH, ScD<sup>2,3,4</sup>, Lisa A  
5 Maier, MD<sup>2,3,4\*</sup>, Tasha E Fingerlin, PhD<sup>1,5\*</sup>.

6

7 \*These authors contributed equally to this work.

8

9 **Institutions:** <sup>1</sup>Colorado School of Public Health, Department of Biostatistics and  
10 Informatics; <sup>2</sup>National Jewish Health, Department of Medicine; <sup>3</sup>University of Colorado,  
11 Department of Medicine; <sup>4</sup>Colorado School of Public Health, Department of Environmental  
12 and Occupational Health; <sup>5</sup>National Jewish Health, Department of Immunology and  
13 Genomic Medicine;

14

15 **Corresponding Author:**

16

17 Nichole E Carlson, PhD  
18 Professor  
19 Department of Biostatistics and Informatics  
20 University of Colorado-Anschutz Medical Campus  
21 13001 E 17<sup>th</sup> PL, MS B-119  
22 Aurora, CO 80045  
23 Tel: 303-724-4354  
24 Fax:303-724-4491  
25 e-mail:nichole.carlson@cuanschutz.edu

26

27

28

29 **Running Head:** Radiomic Profiling of Sarcoidosis of the Lung

30 **Total Word Count:** 3200

31

32 **Supplementary Material Statement:** This article has an online supplement, which is  
33 accessible from this issue's table of contents online.

34

35 **Summary of COI:**

36

37 NEC, WLL, MM, TEF, SL, BB, TEF have received grants from the National Institutes of  
38 Health (R01 HL114587; R01 HL142049; U01 HL112695; U01 HL112707; U01  
39 HL112707, U01 HL112694, U01 HL112695, U01 HL112696, U01 HL112702, U01  
40 HL112708, U01 HL112711, U01 HL112712)

41

42 WLL is additionally support on National Institutes of Health 5T32HL007085

43

44 LAM has received grants from the National Institute of Health (R01HL140357,  
45 R01HL142049, R01 HL114587; U01 HL112695; U01 HL112707; U01 HL112707, U01  
46 HL112694, U01 HL112695, U01 HL112696, U01 HL112702, U01 HL112708, U01  
47 HL112711, U01 HL112712, and R01HL136681), Ann Theodore Foundation, the FSR,  
48 Mallinckrodt Pharmaceuticals, and the University of Cincinnati (Mallinckrodt  
49 Pharmaceuticals Foundation Grant) and serves on the Scientific Advisory Board for  
50 FSR, and Boeringer Ingelheim.

51

52 Funding: This work is supported by NIH grants: R01 HL114587; R01 HL142049; U01  
53 HL112695; U01 HL112707; U01 HL112707, U01 HL112694, U01 HL112695, U01  
54 HL112696, U01 HL112702, U01 HL112708, U01 HL112711, U01 HL112712 and  
55 5T32HL007085

56

57 **Acknowledgements and Author contributions:** NEC is responsible for all content in  
58 the manuscript.

59

60 N.E.C. Substantial contributions to the conception or design of the work, lead  
61 biostatistical analysis and interpretation of the data and wrote manuscript. W.L.  
62 developed the filtering method for this analysis, performed the sensitivity and validation  
63 analyses and edited the manuscript. S.M.R. performed image processing, conducted

64 statistical analysis, prepared figures and table, interpreted the data, and contributed to  
65 the manuscript. M.M. coordinated the study, cleaned data, and contributed to the  
66 manuscript. B.B. supported data acquisition, data cleaning, project management, and  
67 contributed to the manuscript. S.L. contributed to the scientific rationale and  
68 interpretation of the data and contributed to the manuscript. L.A.M. Substantial  
69 contributions to the conception or design of the work, interpretation of the data and  
70 wrote the manuscript. T.E.F. Substantial contributions to the conception or design of the  
71 work, interpretation of the data and wrote the manuscript.

72  
73 This work was supported by the National Institutes of Health (R01 HL114587; R01  
74 HL142049; U01 HL112695; T32HL007085). Data from the GRADS study was used,  
75 which was funded by the NIH grant U01 HL112707 entitled “Sarcoidosis and A1AT  
76 Genomics and Informatics Centre”, as well as others (U01 HL112707, U01 HL112694,  
77 U01 HL112695, U01 HL112696, U01 HL112702, U01 HL112708, U01 HL112711, U01  
78 HL112712). The content is solely the responsibility of the authors and does not  
79 necessarily represent the official views of the National Heart, Lung, and Blood Institute  
80 or the National Institutes of Health.

1 **Key words:** quantitative imaging, texture analysis, pulmonary function, phenotyping,  
2 patient outcomes

3

4 **Abbreviations:**

5 AD – Airway and Vascular Distortion  
6 BMI - body mass index  
7 BVB - bronchovascular bundle  
8 HRCT – High resolution chest computed tomography  
9 CXR – chest X-ray  
10 DLCO - diffusing capacity for carbon monoxide  
11 FEV1 - forced expiratory volume in one second  
12 FEV1/FVC - ratio of FEV1 to FVC  
13 FVC - forced vital capacity  
14 GIC – Genetics and Informatics Core  
15 GLCM – Gray level co-occurrence matrix  
16 GRADS - Genomic Research in Alpha-1 Anti-trypsin Deficiency and Sarcoidosis  
17 IRB - institutional review board  
18 LN – lymphadenopathy  
19 PA - parenchymal abnormalities  
20 PFT – Pulmonary Function Test  
21 QOL – Quality of life  
22 VAS – visual assessment score

23

24 **Abstract**

25 **Background:** High resolution computed tomography (HRCT) of the chest is  
26 increasingly used in clinical practice for sarcoidosis. Visual assessment of chest HRCTs  
27 in patients with sarcoidosis has high inter- and intra-rater variation. Radiomics offers a  
28 reproducible quantitative assessment of HRCT lung parenchyma and could be useful as  
29 an additional summary measure of disease. We develop radiomic profiles on HRCT and  
30 map them to radiologic, clinical, and patient reported outcomes.

31 **Research Question:** Can radiomic analysis of chest HRCT cluster patients into groups  
32 that are related to radiologic, clinical, and patient reported outcomes?

33 **Study Design and Methods:** Three-dimensional radiomic features were calculated on  
34 chest HRCT for both lungs from sarcoidosis cases enrolled in the Genomic Research in  
35 Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study (N=320). Robust and  
36 sparse K-means was used to cluster sarcoidosis cases using their radiomic profiles.  
37 Differences in patterns on visual assessment (VAS) by cluster were identified using chi-  
38 squared tests. Linear regression investigated how pulmonary function tests and patient  
39 reported outcomes differed between clusters with and without adjustment for other  
40 radiologic quantification.

41 **Results:** Radiomic-based clustering identified four clusters associated with both  
42 Scadding stage and Oberstein score ( $P < 0.001$ ). One of the clusters had markedly few  
43 abnormalities. Another cluster had consistently more abnormalities along with more  
44 Scadding stage IV. Average pulmonary function testing (PFT) differed between clusters,  
45 even after accounting for Scadding stage and Oberstein score ( $P < 0.001$ ), with one  
46 cluster having more obstructive disease. The most discriminative radiomic measures  
47 explained 10-15% of the variation in PFT beyond demographic variables. Shortness of  
48 breath, fatigue, and physical health differed by cluster ( $P < 0.014$ ).

49 **Interpretation:** Radiomic quantification of sarcoidosis identifies new subtypes  
50 representative of existing radiologic assessment and more predictive of pulmonary  
51 function. These findings provide evidence that radiomics may be useful for identifying  
52 new imaging-based disease phenotypes.

53

54 **Abstract word count: 295**

55

56 Sarcoidosis is a granulomatous interstitial lung disease which affects ~ 110 thousand  
57 individuals in the United States<sup>1</sup>. Typical diagnosis is between 30-50 years of life,  
58 resulting in decreases in quality of life (QOL) and productivity<sup>2</sup>. Pulmonary disease  
59 occurs in over 90% of those with sarcoidosis<sup>3</sup> with significant morbidity and mortality.  
60 Currently, visual assessment of chest radiography (CXR) is used to quantify lung  
61 abnormalities standardized via the Scadding staging<sup>4</sup>. Substantial variation exists in CT-  
62 based radiographic patterns within each Scadding stage limiting its utility in predicting  
63 prognosis even in the extreme stages<sup>5</sup>.

64  
65 Chest high resolution computed tomography (HRCT) is increasingly used in clinical  
66 practice to monitor disease as it offers more detailed visualization of parenchymal  
67 abnormalities (PA) compared to CXR<sup>4,6-8</sup>. As with CXR, visual assessment of chest  
68 HRCT is used to evaluate abnormalities although there are limited standardized scoring  
69 metrics<sup>4,9,10</sup>. This is due in part to the diverse and heterogeneous patterns present on  
70 chest HRCT in sarcoidosis, often with multiple patterns noted. These complexities result  
71 in high inter- and intra-rater variation<sup>11</sup>. Recently, a Delphi study was undertaken to  
72 define phenotypes based on visual assessment, yet without assessment of clinical  
73 utility<sup>12</sup>. As not all patients have access to expert visual interpretation, more automated  
74 systems that quantify sarcoidosis chest HRCT could decrease variation and make  
75 HRCT more usable in routine clinical care.

76  
77 Radiomics is when large numbers of quantitative features are extracted from medical  
78 images<sup>13</sup>. A radiomics panel computes summary measures of the distribution of the

79 Hounsfield units (HU) along with summary measures of the spatial relationships of  
80 neighboring voxels<sup>14</sup>. The result is a characterization of image texture.

81  
82 Radiomics have proved useful for quantifying HRCT in emphysema<sup>7</sup>, idiopathic  
83 pulmonary fibrosis<sup>15,16</sup>, interstitial lung disease<sup>17,18</sup>, diffuse lung disease<sup>19</sup> and cancer<sup>20</sup>.  
84 Ryan et al.<sup>21</sup> showed the potential utility of radiomics in sarcoidosis, comparing radiomic  
85 measures between sarcoidosis patients and controls. It remains unclear whether  
86 radiomics also has the potential to differentiate varied phenotypes *within* sarcoidosis  
87 patients and how radiomics relates to visual assessment (VAS). Radiomic profiles within  
88 patients with sarcoidosis that correlate with VAS, pulmonary function testing (PFT), and  
89 patient reported outcomes (PRO) would indicate that radiomics may serve as a useful  
90 refined measure to track change in the lung parenchyma over time than is possible with  
91 visual assessment.

92  
93 The goal of this study was to develop a radiomic profile of chest HRCT in sarcoidosis  
94 using a phenotypically-diverse population of sarcoidosis participants from the Genomic  
95 Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study<sup>22</sup>. We  
96 employ statistical clustering techniques and investigate the clinical utility of the clusters  
97 by quantifying their association with VAS, PFT and PRO<sup>23,24</sup>.

98

## 99 **Study Design and Methods**

100

101 *Study design and participants*



102

103 The sarcoidosis population was recruited in the multicenter NHLBI-funded GRADS  
104 study<sup>22</sup> as cross-sectional observational cohort (N=368). This ancillary study has  
105 GRADS approval and all participants provided informed consent (IRB approval HS-2779  
106 and HS-2780). More details of this cohort can be found in e-Appendix 1.

107

108 To comply with image biomarker standardization initiative (IBSI) recommendations<sup>25</sup>  
109 details of the HRCT acquisition, processing and segmentation can be found in e-  
110 Appendix 1 and e-Tables 1 and 2. GRADS' visual assessment score (VAS; Table 3, e-  
111 Appendix 1, e-Tables 3 and 4) was used to quantify overall Oberstein score<sup>5,22</sup> along  
112 with additional information regarding presence of lymphadenopathy (LN), airway and  
113 vasculature distortion (AD), and PA (Table 3). Scadding stage was evaluated at the site  
114 using CXR (e-Appendix1).

115

116 PFT included pre-bronchodilator (pre-BD) forced expiratory volume at one second  
117 (FEV1), forced vital capacity (FVC), the ratio of FEV1 to FVC, and post-BD diffusing  
118 capacity of the lungs for carbon monoxide (DLCO). The PROs included the  
119 gastroesophageal reflux disease questionnaire (GERDQ)<sup>26</sup>, the University of California  
120 San Diego Shortness of Breath Questionnaire (SOBQ)<sup>27</sup>, two measures of fatigue (the  
121 Fatigue Assessment Scale [FAS]<sup>28</sup> and Patient-Reported Outcomes Measurement  
122 Information System fatigue profile [PROMIS]<sup>29</sup>), the Cognitive Failure Questionnaire  
123 (CFQ)<sup>30</sup>, and the SF-12<sup>31,32</sup> physical and mental subscales. The final analysis dataset  
124 included N=320 patients who had an analyzable HRCT and clinical data (e-Figure 1).

125

126 *Radiomic Analysis*

127 We computed 44 first-order and 239 gray-level co-occurrence matrix (GLCM) radiomic  
128 features on each lung (566 features) using the lungct and RIA packages in R<sup>33–36</sup>.  
129 These are open-source packages with published documentation and permit perfect  
130 reproducibility with transparent implementation, aligning with IBSI goals. Furthermore,  
131 this allowed a fully R based analysis pipeline and provided a more comprehensive  
132 radiomic panel. Radiomic features beyond those typically used in neuroscience and  
133 cancer and previously standardized by IBSI may be important in diffuse pulmonary  
134 disease. For consistency with package documentation, we use the nomenclature of the  
135 RIA package.

136

137 To calculate the gray level co-occurrence matrix (GLCM) features, the Hounsfield units  
138 from each HRCT were discretized into 16 bins with equal relative frequencies; then, the  
139 features were calculated in 13 directions, assuming a voxel distance of one; these  
140 features were summarized using the mean statistic<sup>34,35</sup>.

141

142 The R ez.combat function harmonized radiomic measures across scanners<sup>37–39</sup>, while  
143 preserving the biological variability in age, height, BMI, sex, race-ethnicity and GRADS  
144 phenotype (e-Table 2).

145

146 Radiomic features were high-dimensional and repetitive (Figure 1). We used a  
147 decorrelation filter<sup>40</sup> (e-Appendix 1) that prioritized first-order over second-order features

148 to identify a representative feature subset for analysis. This reduced the features to 99.  
149 We used robust and sparse k-means<sup>41</sup> to cluster participants (R package, RSKC). For  
150 outlier robustness, trimming was set at 0.1. The optimal bound on feature weights (9.5)  
151 and number of clusters (4) were simultaneously selected using a permutation approach  
152 and BCS-based Gap statistic<sup>41</sup> after standardization<sup>42</sup>. Standardization was performed  
153 with respect to the permutation reference to permit comparability across bounds and  
154 cluster numbers. The top five discriminative features were selected for further  
155 investigation.

### 156 *Statistical Analysis and Validation*

157 Descriptive statistics on VAS were computed by cluster and simulated Fisher's exact  
158 tests used to assess cluster differences. Linear regression quantified associations  
159 between cluster, Scadding stage, and Oberstein Score, and each of the outcomes. We  
160 fitted univariable models with cluster, Scadding stage, or Oberstein score and then  
161 modeled them together to determine if cluster association remained significant  
162 accounting for other radiologic findings. Each outcome was modelled separately using a  
163 complete case analysis. Linear regression quantified associations between  
164 discriminative features and outcomes. All models were adjusted for age, sex,  
165 race/ethnicity (e-Appendix 1), height, and BMI. Analyses were conducted in R<sup>36</sup>.

166

167 This work was an unsupervised problem, which made traditional training and test  
168 validation approaches difficult given unknown true groupings. Instead, we conducted  
169 internal validation by applying our analysis pipeline under various conditions and with  
170 bootstrapped samples (e-Appendix 1).

171

## 172 **Results**

173 Tables 1-2 shows the characteristics of the study population (N=320), 146 (46%) self-  
174 identified as male, 220 (68.8%) self-identified as non-Hispanic white, 76 (24%) as black,  
175 15 (4.7%) as Hispanic, and 9 (2.8%) as one of Asian, American Indian, Alaska Native,  
176 not identifying a single primary race or missing (N=2). The average age was 53 (SD=10)  
177 years, average height 67.0 in (SD=4.0) and average BMI 30.6 kg/m<sup>2</sup> (SD=6.5). By  
178 design participants spread across Scadding stages, with 43 (14%) stage 0, 63 (20%)  
179 stage 1, 92 (29%) stage 2, 44 (14%) stage 3 and 75 (24%) stage 4. The average FEV1  
180 was 2.62 L (SD=0.89), FVC 3.57 L (SD=1.07), and DLCO 80.31 (SD=23.97). The  
181 population predominantly demonstrated non-obstructive FEV1/FVC ratio (N=235; 73%).

182

### 183 *Radiomic Based Clustering*

184 We identified four clusters (Table 1). Ordered from highest FVC to lowest, 56 (17.5%)  
185 patients were cluster 1, 110 (34.3%) cluster 2, 54 (16.9%) cluster 3, and 100 (31.3%)  
186 cluster 4. Cluster was associated with Scadding stage ( $P<0.001$ ), but not a direct  
187 reflection of Scadding stage (Table 1). Descriptively, cluster 3 had the highest  
188 percentage of Scadding stage IV (48%). Clusters 1 and 2 each had approximately 60%  
189 of the patients with a Scadding stage of I or II, a higher proportion of stage 0, and  
190 limited Scadding stage IV present. Cluster 3 had the second highest observed Scadding  
191 stage IV (40%) with a similar percentage of Scadding stage II compared to clusters 1  
192 and 2 (~30%).

193

### 194 *Radiomic clustering and VAS*

195 When descriptively investigating VAS patterns, the clusters reflected increased  
196 presence of VAS abnormalities with cluster 1 having low presence of nearly all airway  
197 and vascular distortions (AD) and PA and much lower average Oberstein scores than  
198 clusters 2-4 (Table 3;  $P < 0.001$ ). Cluster 2 reflected some increase in AD and PA with  
199 clusters 3 and 4 having a higher presence of AD and PA. For example, cluster 4 had at  
200 least double the presence of AD and PA compared to cluster 2. After adjustment for  
201 demographics, average Oberstein score for cluster 3 was 1.98 (SE=0.48) units and  
202 cluster 4 was 3.15 (SE=0.39) units higher than cluster 2 ( $p < 0.001$ ).

203

#### 204 *Associations with PFT and PRO*

205 After adjustment for demographics, average PFT differed between clusters (Figure 2;  
206  $P < 0.001$ ). Clusters 2 and 3 had ~0.3 L lower average FVC compared to clusters 1 and 4  
207 had ~0.9 L lower average FVC compared to cluster 1. Cluster 2 had ~0.2 L lower  
208 average FVC compared to cluster 1 and cluster 3 had a larger decline with an average  
209 FEV1 ~0.5 L lower than cluster 1. Cluster 4 had the lowest average FEV1 and ~0.8 L  
210 lower than cluster 1. DLCO had a similar pattern to FVC. Cluster 3 had the most  
211 FEV1/FVC based obstruction (54%) with clusters 1 and 2 having the same amount of  
212 obstruction (16%) and cluster 4 falling in the middle (32%).

213

214 After adjustment for demographics, PROs also differed between clusters but not  
215 consistently (Figure 3). Fatigue and Average shortness of breath (SOBQ) differed  
216 between clusters ( $P < 0.014$ ). Clusters 2 and 4 had a fatigue score that was more than 3

217 units lower on average compared to cluster 1 ( $p < 0.016$ ). Cluster 4 also had an average  
218 SOBQ ~12 units higher than cluster 1 ( $p = 0.003$ ).

219

220 The clusters remained significantly associated with PFT after adjusting for Scadding  
221 stage (Figure 2;  $P < 0.001$ ) or Oberstein score (Figure 2;  $P < 0.001$ ) and after adjusting for  
222 both simultaneously (Figure 2;  $P < 0.001$ ). Oberstein score was not significantly  
223 associated with FVC after adjustment for cluster ( $P = 0.59$ ) and became even less  
224 significant after further adjustment for Scadding stage ( $P = 0.88$ ). However, Scadding  
225 stage was significantly associated with FVC after adjustment for cluster and Oberstein  
226 score ( $P = 0.019$ ). The findings for Oberstein score with DLCO were like those of FVC.  
227 For FEV1, Oberstein score was still significantly associated after adjustment for cluster  
228 ( $P = 0.011$ ) but became insignificant after additional adjustment for Scadding stage  
229 ( $P = 0.21$ ). Scadding stage remained significant in all models ( $P < 0.001$ ). For FEV1/FVC,  
230 all three assessments (radiomics, Scadding, and Oberstein score) were significant  
231 ( $P < 0.016$ ).

232

233 Cluster also remained associated with fatigue and SOBQ score after adjustment for  
234 Scadding and Oberstein ( $P < 0.038$ ; Figure 3).

235

236 The five most discriminatory radiomic features included kurtosis, which is a measure of  
237 shape of the distribution of the HU from an image, as well as four summary measures  
238 from the gray level co-occurrence matrix (GLCM). The GLCM measure spatial  
239 correlation and similarity of the HU in image voxels near each other. Image visualization

240 of cases with different values of kurtosis and two GLCM measures are shown in Figure  
241 4 with distribution of HU in e-Figure 2 for maximum, median and minimum kurtosis  
242 levels in our population. The images visibly show the increase in observable PA (Figure  
243 4) with lower kurtosis. In addition, Figure 5 shows how Oberstein Score separates  
244 based on kurtosis and GLCM Min. GLCM Min appears to be most related to severity  
245 with higher Oberstein score mapping with higher GLCM Min and Scadding stage is, in  
246 general, not associated with either measure.

247  
248 The discriminatory radiomic measures were jointly associated with FVC, FEV1,  
249 FEV1/FVC and DLCO ( $P < 0.001$ ; Table 4 and e-Table 5 for PRO). The radiomic  
250 measures explained between 10 to 15% more variation in PFT than adjustment for  
251 demographics (age, race, sex, height and BMI) only. For comparison, Scadding stage  
252 explained between 4% and 12% more variation in PFT and Oberstein score explained  
253 between 2% and 8% more variation in PFT.

254  
255 *Validation of Clustering*  
256 Detailed results can be found in e-Appendix 2, e-Figure 3. The validation analysis  
257 suggested only mild sensitivity of clustering to the analysis pipeline. There is more  
258 sensitivity to bootstrapped samples in how the sample is divided into clusters; however,  
259 cluster consistently remained a significant predictor of FVC across all sources of  
260 random perturbations in the pipeline. In all validation cases the proportions of  $P$ -values  
261 less than 0.01 were 100%.

262

## 263 **Discussion**

264 Radiographic manifestations in sarcoidosis are protean. As a result, traditionally VAS is  
265 used for image characterization and not standardized. The utility of VAS in sarcoidosis  
266 is limited by the intra-observer and inter-observer variability. Radiomics is a more  
267 reproducible and computationally efficient approach to characterize HRCT. We used  
268 radiomics to characterize images from a large, phenotypically diverse cohort of  
269 sarcoidosis subjects and demonstrated that radiomics are associated with VAS, clinical  
270 and patient reported outcomes of disease. Using a common unsupervised learning  
271 approach<sup>41</sup>, we identified four radiomic based clusters. These clusters differed  
272 significantly by PFT, fatigue, and shortness of breath, two PROs. Notably, each cluster  
273 included a range of Scadding stages and cluster remained significantly associated with  
274 PFT after accounting for Scadding stage and Oberstein score. These data suggest that  
275 radiomics represents radiographic abnormalities that differ from Scadding stage and  
276 may be a better representation of image characterization to explain PFT and PRO.

277

278 A holistic assessment of the clusters showed two lower severity and two higher severity  
279 clusters (Table 5). One high severity cluster (4) had significant fibrosis, substantial  
280 presence of AD and PA on VAS, and decreased PFT, which resulted in more shortness  
281 of breath and fatigue. Cluster 3 represented those with obstructive spirometry and more  
282 presence of AD and PA than clusters 1 and 2, moderate fibrosis, and the lowest  
283 FEV1/FVC ratio. These interpretations have similarities to another recent attempt to  
284 subtype using clinical characteristics<sup>43</sup>. Unlike our work, that work had no radiomics or  
285 VAS. We both several low severity clusters with minimal PA. We both found an



286 obstructive cluster and a severe fibrotic cluster. More recently, HRCT VAS phenotypes  
287 were proposed via a Delphi consensus study<sup>12</sup>. That work defined two major groups,  
288 those with fibrotic versus non-fibrotic findings, similar to our clusters with fibrotic (3 and  
289 4) versus more non-fibrotic (1 and 2) findings. However, the VAS of their various  
290 subtypes of non-fibrotic and fibrotic CT findings were included in a number of our  
291 clusters. This may reflect the power in our sample size to define subtypes or possibly  
292 that these phenotypes or VAS overlap as noted in our study.

293  
294 Demographic characteristics of the individual explained a sizable amount of the  
295 variation observed in PFT ( $R^2=50-60\%$ ). Radiomics also explained a significant amount  
296 of additional variation in PFT (10-50%). This additional amount of variation explained is  
297 consistent with other quantitative imaging approaches such as CALIPER<sup>17</sup> and those  
298 used for investigations of other lung conditions such as systemic sclerosis<sup>44</sup> and diffuse  
299 interstitial lung diseases<sup>45</sup>.

300  
301 Except in lung cancer research, much of the quantitative CT image analysis has  
302 focused on HU density<sup>18,44</sup>. We included summarization of both density and spatial  
303 characterization. More measures of GLCM appeared discriminative in the cluster  
304 analysis than densitometry measures. This implies that texture is perhaps more useful  
305 for differentiating PA in sarcoidosis.

306  
307 Although it remains speculative as to why decreased kurtosis is associated with  
308 decreased FVC and DLCO, it is plausible that as kurtosis decreases, more severe PA

309 are present that impact lung function. As kurtosis decreases, more severe PA are visual  
310 present that may impact the function of the lung (Figure 4). Severe PA in sarcoidosis  
311 are observed as higher HU values. In e-Figure we observed the presence of a higher  
312 frequency of higher HU values dampening the peak in the HU distribution and leading to  
313 a lower kurtosis. In addition, GLCM Min appears likely to measure disease severity  
314 based on the visual patterns with Oberstein in Figure 5.

315

316 The associations with cluster and PROs were less consistent, although important  
317 patterns emerged. Cluster 4 demonstrated decreased QOL (SF-12 physical) and worse  
318 shortness of breath (SOBQ), findings that are consistent with worse lung function and  
319 VAS scores in this cluster. Cluster explained substantially less variation in PROs (0 to  
320 8%) compared to PFTs. While the tools we used to measure PROs are validated and  
321 used widely in sarcoidosis, they are not generally correlated with objective measures of  
322 lung function<sup>46</sup>. As an example, fatigue is a known multi-factorial PRO in sarcoidosis  
323 and may impact a number of other PRO<sup>46,47</sup>. Our finding that cluster is associated with  
324 decreased physical function and increased shortness of breath provides  
325 encouragement that more detailed characterization of lung abnormalities, like we  
326 developed here, could contribute to a better understanding of the current disconnect  
327 between measures of lung function and patient experiences.

328

329 This study had several strengths. To our knowledge, this was the largest cluster of  
330 sarcoidosis patients with research grade HRCT available allowing for a full 3-D based  
331 quantitative analysis. Radiomic and other quantitative imaging approaches have a major

332 strength in that they can be computed in a time efficient and reliable, reproducible  
333 automated procedure. The radiomics package in R took only 3 minutes to compute all  
334 the 3-D radiomics measures. This means large quantities of scans can have radiomic  
335 profiles computed for aiding in decisions on what scans the radiologist might prioritize  
336 for further consideration for visual or clinician evaluation.

337  
338 In addition to the high-quality and robust clinical data, the GRADS study also provides a  
339 comprehensive and consistently collected set of patient reported outcomes, which  
340 reflect important aspects of treatment decision-making processes<sup>48</sup>. The results  
341 internally validated suggest our approach is not over fitting these data.

342  
343 This study is not without limitations. The GRADS study relied on enrollment from  
344 academic centers and could be skewed to a population that was referred for worse  
345 disease or was near one of the centers, which were primarily localized to the Eastern  
346 US. The demographic is predominantly white and of higher SES as a result and thus  
347 may not provide full representation of the spectrum of disease. In addition, many  
348 subjects had disease for a decade or longer and were treated. While the same protocol  
349 was used across study sites for obtaining the CT images we studied, the scanners  
350 themselves differed. Harmonization was performed to mitigate systematic differences  
351 due to scanner type. In addition, the distribution of PFT measures is not dependent on  
352 scanner type. As such, we expect any differences in the radiomic measures due to  
353 scanner type to be non-differential as they relate to PFTs. Finally, the number of  
354 clusters we identified may not directly translate to other populations of sarcoidosis or be

355 the unique optimal solution. There are multiple ways to choose the optimal number of  
356 clusters. We used an alternative radiomics package with a broader set of measures.  
357 However, not all these measures were part of IBSI work. We used open-source  
358 software accessible to any reader for verification of our findings and to conduct  
359 comparisons with other software.

360

### 361 **Interpretation**

362 In summary, this work provides evidence that in sarcoidosis radiomic quantification is  
363 useful for classifying abnormality of the lung along with pulmonary function and to a  
364 lesser degree patient reported outcomes. Future work should evaluate the potential of  
365 radiomics to capture small changes over time not easily detected by other assessment  
366 to further evaluate the potential of radiomics serving as a clinically useful quantitative  
367 measure of sarcoidosis presentation and progression.

368

## 369 References

- 370 1. Erdal BS, Clymer BD, Yildiz VO, Julian MW, Crouser ED. Unexpectedly high  
371 prevalence of sarcoidosis in a representative U.S. Metropolitan population. *Respir*  
372 *Med* 2012;106(6):893–899.
- 373 2. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health  
374 Questionnaire: a new measure of health-related quality of life. *Am J Respir Crit*  
375 *Care Med* 2003;168(3):323–329.
- 376 3. Wasfi YS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity.  
377 *Chest* 2006;129(5):1234–1245.
- 378 4. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136  
379 cases after five years' observation. *Br Med J* 1961;2(5261):1165–1172.
- 380 5. Oberstein A, Zitzewitz H von, Schweden F, Müller-Quernheim J. Non invasive  
381 evaluation of the inflammatory activity in sarcoidosis with high-resolution computed  
382 tomography. *Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG* 1997;14(1):65–72.
- 383 6. Drent M, De Vries J, Lenters M, et al. Sarcoidosis: assessment of disease severity  
384 using HRCT. *Eur Radiol* 2003;13(11):2462–2471.
- 385 7. Sluimer I, Schilham A, Prokop M, Ginneken B van. Computer analysis of computed  
386 tomography scans of the lung: a survey. *IEEE Trans Med Imaging* 2006;25(4):385–  
387 405.
- 388 8. Keijsers RGM, Heuvel DAF van den, Grutters JC. Imaging the inflammatory activity  
389 of sarcoidosis. *Eur Respir J* 2013;41(3):743–751.
- 390 9. Moller DR. Negative clinical trials in sarcoidosis: failed therapies or flawed study  
391 design? *Eur Respir J* 2014;44(5):1123–1126.
- 392 10. Nunes H, Uzunhan Y, Gille T, Lamberto C, Valeyre D, Brillet P-Y. Imaging of  
393 sarcoidosis of the airways and lung parenchyma and correlation with lung function.  
394 *Eur Respir J* 2012;40(3):750–765.
- 395 11. Van den Heuvel DA, Jong PA de, Zanen P, et al. Chest Computed Tomography-  
396 Based Scoring of Thoracic Sarcoidosis: Inter-rater Reliability of CT Abnormalities.  
397 *Eur Radiol* 2015;25(9):2558–2566.
- 398 12. Desai SR, Sivarasan N, Johannson KA, et al. High-resolution CT phenotypes in  
399 pulmonary sarcoidosis: a multinational Delphi consensus study. *Lancet Respir Med*  
400 [Internet] 2023 [cited 2024 Jan 9];0(0). Available from:  
401 [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(23\)00267-](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00267-9/fulltext)  
402 [9/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00267-9/fulltext)

- 403 13. Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. *Magn*  
404 *Reson Imaging* 2012;30(9):1234–1248.
- 405 14. Haralick RM. Statistical and structural approaches to texture. *Proc IEEE*  
406 1979;67(5):786–804.
- 407 15. Park YS, Seo JB, Kim N, et al. Texture-based quantification of pulmonary  
408 emphysema on high-resolution computed tomography: comparison with density-  
409 based quantification and correlation with pulmonary function test. *Invest Radiol*  
410 2008;43(6):395–402.
- 411 16. Humphries SM, Yagihashi K, Huckleberry J, et al. Idiopathic Pulmonary Fibrosis:  
412 Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month  
413 Follow-up. *Radiology* 2017;285(1):270–278.
- 414 17. Ungprasert P, Wilton KM, Ernste FC, et al. Novel Assessment of Interstitial Lung  
415 Disease Using the “Computer-Aided Lung Informatics for Pathology Evaluation and  
416 Rating” (CALIPER) Software System in Idiopathic Inflammatory Myopathies. *Lung*  
417 2017;195(5):545–552.
- 418 18. Ash SY, Harmouche R, Vallejo DLL, et al. Densitometric and local histogram based  
419 analysis of computed tomography images in patients with idiopathic pulmonary  
420 fibrosis. *Respir Res* [Internet] 2017 [cited 2018 Jan 8];18. Available from:  
421 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340000/>
- 422 19. Wang J, Li F, Doi K, Li Q. Computerized detection of diffuse lung disease in MDCT:  
423 the usefulness of statistical texture features. *Phys Med Biol* 2009;54(22):6881–  
424 6899.
- 425 20. Lee G, Lee HY, Park H, et al. Radiomics and its emerging role in lung cancer  
426 research, imaging biomarkers and clinical management: State of the art. *Eur J*  
427 *Radiol* 2017;86:297–307.
- 428 21. Ryan SM, Fingerlin TE, Mroz M, et al. Radiomic measures from chest high-  
429 resolution computed tomography associated with lung function in sarcoidosis. *Eur*  
430 *Respir J* 2019;54(2).
- 431 22. Moller DR, Koth LL, Maier LA, et al. Rationale and Design of the Genomic  
432 Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study.  
433 Sarcoidosis Protocol. *Ann Am Thorac Soc* 2015;12(10):1561–1571.
- 434 23. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K.  
435 Examination of the Dimensionality of Fatigue: The Construction of the Fatigue  
436 Assessment Scale (FAS). *Eur J Psychol Assess* 2004;20(1):39–48.
- 437 24. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement  
438 Information System (PROMIS) developed and tested its first wave of adult self-

- 439 reported health outcome item banks: 2005-2008. *J Clin Epidemiol*  
440 2010;63(11):1179–1194.
- 441 25. Zwanenburg A, Vallières M, Abdalah MA, et al. The Image Biomarker  
442 Standardization Initiative: Standardized Quantitative Radiomics for High-  
443 Throughput Image-based Phenotyping. *Radiology* 2020;295(2):328–338.
- 444 26. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the  
445 diagnosis and management of gastro-oesophageal reflux disease in primary care.  
446 *Aliment Pharmacol Ther* 2009;30(10):1030–1038.
- 447 27. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a New  
448 Dyspnea Measure: The UCSD Shortness of Breath Questionnaire. *Chest*  
449 1998;113(3):619–624.
- 450 28. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K.  
451 Examination of the Dimensionality of Fatigue: The Construction of the Fatigue  
452 Assessment Scale (FAS). *Eur J Psychol Assess* 2004;20(1):39–48.
- 453 29. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement  
454 Information System (PROMIS) developed and tested its first wave of adult self-  
455 reported health outcome item banks: 2005-2008. *J Clin Epidemiol*  
456 2010;63(11):1179–1194.
- 457 30. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures  
458 Questionnaire (CFQ) and its correlates. *Br J Clin Psychol* 1982;21(1):1–16.
- 459 31. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey:  
460 Construction of Scales and Preliminary Tests of Reliability and Validity. *Med Care*  
461 1996;34(3):220–233.
- 462 32. Ware J, Kosinski M, Turner-Bowker D, Gandek B. How to score SF-12 items. *SF-  
463 12 V2 Score Version 2 SF-12 Health Surv* 2002;29–38.
- 464 33. Ryan SM, Vestal B, Maier LA, Carlson NE, Muschelli J. Template Creation for  
465 High-Resolution Computed Tomography Scans of the Lung in R Software. *Acad  
466 Radiol* 2020;27(8):e204–e215.
- 467 34. Kolossváry M, Kellermayer M, Merkely B, Maurovich-Horvat P. Cardiac Computed  
468 Tomography Radiomics: A Comprehensive Review on Radiomic Techniques. *J  
469 Thorac Imaging* 2018;33(1):26–34.
- 470 35. Kolossváry M, Karády J, Szilveszter B, et al. Radiomic Features Are Superior to  
471 Conventional Quantitative Computed Tomographic Metrics to Identify Coronary  
472 Plaques With Napkin-Ring Sign. *Circ Cardiovasc Imaging* 2017;10(12):e006843.

- 473 36. R Core Team. R: A Language and Environment for Statistical Computing [Internet].  
474 Vienna, Austria: R Foundation for Statistical Computing; 2018. Available from:  
475 <https://www.R-project.org/>
- 476 37. Fortin J-P, Parker D, Tunç B, et al. Harmonization of multi-site diffusion tensor  
477 imaging data. *NeuroImage* 2017;161:149–170.
- 478 38. Fortin J-P, Cullen N, Sheline YI, et al. Harmonization of cortical thickness  
479 measurements across scanners and sites. *NeuroImage* 2018;167:104–120.
- 480 39. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression  
481 data using empirical Bayes methods. *Biostat Oxf Engl* 2007;8(1):118–127.
- 482 40. Lippit WL. Clustering with Highly Correlated Features. *MS Thesis Univ Colo* 2022;
- 483 41. Kondo Y, Salibian-Barrera M, Zamar R. RSKC : An R Package for a Robust and  
484 Sparse K-Means Clustering Algorithm. *J Stat Softw* [Internet] 2016 [cited 2020 May  
485 27];72(5). Available from: <http://www.jstatsoft.org/v72/i05/>
- 486 42. Witten DM, Tibshirani R. A framework for feature selection in clustering. *J Am Stat*  
487 *Assoc* 2010;105(490):713–726.
- 488 43. Lin NW, Arbet J, Mroz MM, et al. Clinical phenotyping in sarcoidosis using cluster  
489 analysis. *Respir Res* 2022;23(1):88.
- 490 44. Camiciottoli G, Orlandi I, Bartolucci M, et al. Lung CT Densitometry in Systemic  
491 Sclerosis: Correlation With Lung Function, Exercise Testing, and Quality of Life.  
492 *Chest* 2007;131(3):672–681.
- 493 45. Shin KE, Chung MJ, Jung MP, Choe BK, Lee KS. Quantitative Computed  
494 Tomographic Indexes in Diffuse Interstitial Lung Disease: Correlation With  
495 Physiologic Tests and Computed Tomography Visual Scores. *J Comput Assist*  
496 *Tomogr* 2011;35(2):266–271.
- 497 46. Thunold RF, Løkke A, Cohen AL, Hilberg O, Bendstrup E. Patient Reported  
498 Outcome Measures (PROMs) in Sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis*  
499 2017;34(1):2–17.
- 500 47. Kampstra NA, Grutters JC, Beek FT van, et al. First patient-centred set of  
501 outcomes for pulmonary sarcoidosis: a multicentre initiative. *BMJ Open Respir Res*  
502 2019;6(1):e000394.
- 503 48. Wijsenbeek MS, Culver DA. Treatment of Sarcoidosis. *Clin Chest Med*  
504 2015;36(4):751–767.
- 505



506 **Take-Home Points**

507 Study Question: Is radiomics a useful quantitative approach for defining radiographic  
508 subtypes in sarcoidosis?

509 Results: Radiomics find four radiographic subtypes in sarcoidosis that are related to  
510 visual assessment and more predictive of clinical measures such as pulmonary function  
511 that visual assessment.

512 Interpretation: Radiomics analysis suggests four subtypes of sarcoidosis ranging from  
513 low severity with limited radiographic abnormality and normal pulmonary function to  
514 severe with significant abnormality on chest CT and either obstruction based on  
515 pulmonary function or reduced pulmonary function with fibrotic presentation on image.

516

517

518 **Table 1:** Patient demographics by radiomic cluster, ordered from least severe (1) to

519 most severe (4) based on average FVC. Unless otherwise noted values are mean (SD).

Characteristic	N	Overall	1	2	3	4	P-value
<b>Sample Size</b>		320	56	110	54	100	
<b>FVC (L)</b>	6	3.57 (1.14)	3.91 (1.16)	3.88 (1.08)	3.61 (1.27)	3.02 (0.92)	<0.001
<b>Age (yr)</b>	0	52.9 (9.9)	49.8 (10.6)	53.1 (9.9)	52.5 (9.8)	54.8 (9.3)	0.026
<b>Female; N (%)</b>		174 (54%)	37 (66%)	52 (47%)	36 (67%)	49 (49%)	0.021
<b>Race/Ethnicity; N (%)</b>	0						0.033
<b>Asian, American Indian, Alaska Native, or not identifying a single primary race</b>		9 (2.8%)	0 (0%)	4 (3.6%)	1 (1.9%)	4 (4.0%)	
<b>Black</b>		76 (24%)	12 (21%)	16 (15%)	13 (24%)	35 (35%)	
<b>Hispanic</b>		15 (4.7%)	2 (3.6%)	6 (5.5%)	1 (1.9%)	6 (6.0%)	
<b>White</b>	0	220 (69%)	42 (75%)	84 (76%)	39 (72%)	55 (55%)	
<b>Height (in)</b>	0	67.0 (4.0)	66.3 (4.2)	67.7 (4.2)	66.5 (3.7)	66.9 (3.7)	0.13
<b>BMI (kg/m<sup>2</sup>)</b>	0	30.6 (6.5)	30.2 (7.4)	32.6 (5.7)	27.0 (5.8)	30.7 (6.4)	<0.001
<b>Scadding; N (%)</b>	3						<0.001
<b>0</b>		43 (14%)	9 (16%)	25 (23%)	4 (7.5%)	5 (5.0%)	
<b>I</b>		63 (20%)	16 (29%)	31 (29%)	7 (13%)	9 (9.0%)	
<b>II</b>		92 (29%)	17 (30%)	32 (30%)	15 (28%)	28 (28%)	
<b>III</b>		44 (14%)	12 (21%)	16 (15%)	6 (11%)	10 (10%)	
<b>IV</b>		75 (24%)	2 (3.6%)	4 (3.7%)	21 (40%)	48 (48%)	

520

521 **Table 2:** Summary measures of pulmonary function testing and self-reported outcomes  
 522 by radiomic cluster ordered from least severe (1) to most severe (4) based on average  
 523 FVC. Unless otherwise noted values are mean (SD).

524

	<b>N Miss</b>	<b>Overall</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>P- value</b>
<b>Sample Size</b>		320	56	110	54	100	
<b>FEV1 (L)</b>	6	2.62 (0.05)	2.98 (0.13)	2.96 (0.08)	2.44 (0.15)	2.14 (0.07)	<0.001
<b>FVC (L)</b>	6	3.57 (0.06)	3.91 (0.16)	3.88 (0.10)	3.61 (0.18)	3.02 (0.09)	<0.001
<b>FEV1/FVC (%)</b>	6	0.73 (0.01)	0.76 (0.01)	0.77 (0.01)	0.67 (0.02)	0.71 (0.01)	<0.001
<b>Obstructive Type<sup>a</sup>; N (%)</b>	6	85 (27%)	9 (16%)	17 (16%)	27 (54%)	32 (32%)	<0.001
<b>DLCO (mL/min/mmHg)</b>	18	22.07 (0.45)	24.13 (1.03)	25.33 (0.66)	21.30 (1.01)	17.56 (0.76)	<0.001
<b>FAS<sup>a</sup></b>	140	29.77 (0.41)	32.46 (1.29)	28.95 (0.66)	30.06 (0.91)	29.24 (0.65)	0.038
<b>GERDQ<sup>b</sup></b>	1	7.07 (0.12)	7.04 (0.30)	7.09 (0.17)	6.72 (0.27)	7.25 (0.23)	0.5
<b>CFQ<sup>c</sup></b>	3	32.79 (0.95)	34.57 (1.87)	34.14 (1.58)	32.50 (2.22)	30.44 (1.93)	0.4
<b>SOBQ<sup>d</sup></b>	17	26.28 (1.31)	22.08 (3.13)	19.94 (1.80)	26.98 (3.12)	35.04 (2.56)	<0.001
<b>PROMIS Fatigue<sup>e</sup></b>	38	25.51 (0.52)	25.82 (1.28)	23.96 (0.82)	26.80 (1.35)	26.18 (0.93)	0.2
<b>SF12-Physical<sup>f</sup></b>	6	41.70 (0.63)	44.78 (1.55)	42.23 (1.10)	42.80 (1.49)	38.77 (1.07)	0.009
<b>SF12-Mental<sup>h</sup></b>	6	48.12 (0.56)	47.13 (1.21)	48.60 (0.90)	47.33 (1.49)	48.56 (1.09)	0.7

525

526 <sup>a</sup>FAS range 5 – 50, higher values indicate more fatigue; <sup>b</sup>GERDQ range 0 – 18, higher values

527 indicate a higher likelihood of GERD; <sup>c</sup>CFQ range 0 -100, higher indicates more cognitive

528 failure; <sup>d</sup> SOBQ range 0 – 120, higher values indicate more shortness of breath; <sup>e</sup> PROMIS

529 Fatigue range 10-50, higher values indicate more fatigue; <sup>f</sup> SF12-Physical-For general U.S.

530 population, mean = 50, SD = 10 and higher values indicate better physical QOL; <sup>9</sup>SF12-Mental-  
531 For general U.S. population, mean = 50, SD = 10 and higher values indicate better mental  
532 QOL.  
533

534 **Table 3:** Distribution of VAS measures by radiomic cluster. Three participants were missing  
 535 VAS and Scadding stage. All measures represent the abnormality was present (vs. absent) and  
 536 are presented as N (%) unless otherwise noted. LN = lymphadenopathy; BVB =  
 537 Bronchovascular Bundle

538

Characteristic	Overall	1	2	3	4	P-value
<b>Sample Size</b>	<b>317</b>	<b>56</b>	<b>108</b>	<b>53</b>	<b>100</b>	
<b>Mediastinal LN</b>	172 (54%)	19 (34%)	60 (56%)	29 (55%)	64 (64%)	0.003
<b>Hilar LN</b>	135 (43%)	14 (25%)	46 (43%)	26 (49%)	49 (49%)	0.017
<b>Micronodule</b>	147 (46%)	23 (41%)	46 (43%)	29 (55%)	49 (49%)	0.4
<b>Airway and Vascular Distortion (AD)</b>						
<b>BVB Distortion</b>	202 (64%)	19 (34%)	53 (49%)	43 (81%)	87 (87%)	<0.001
<b>Traction Bronchiectasis</b>	129 (41%)	6 (11%)	25 (23%)	32 (60%)	66 (66%)	<0.001
<b>Parenchymal Opacity and Distortion (PD)</b>						
<b>Ground Glass</b>	110 (35%)	5 (8.9%)	22 (20%)	21 (40%)	62 (62%)	<0.001
<b>Honeycombing</b>	25 (7.9%)	0 (0%)	2 (1.9%)	4 (7.5%)	19 (19%)	<0.001
<b>Reticular Abnormality</b>	88 (28%)	3 (5.4%)	17 (16%)	21 (40%)	47 (47%)	<0.001
<b>Mosaic Attenuation</b>	86 (27%)	10 (18%)	18 (17%)	14 (26%)	44 (44%)	<0.001
<b>Interlobular Septal Thickening</b>	54 (17%)	5 (8.9%)	14 (13%)	7 (13%)	28 (28%)	0.007
<b>Oberstein Overall; Mean (SE)</b>	4.23 (0.18)	2.11 (0.32)	2.95 (0.26)	5.32 (0.44)	6.23 (0.28)	<0.001

539  
 540

541 **Table 4: Results of the multivariable regression analysis (coefficients and SE's) of**  
 542 **the five discriminatory radiomic measures for PFT.<sup>d</sup>**

	GLCM Gaussian	GLCM Inv Gaussian-E	Kurtosis	GLCM Sum Energy	GLCM Min	P-value	Rsq	Rsq - base
<b>FVC</b>	-0.02 (0.11)	-0.06 (0.08)	<b>0.44 (0.08)<sup>a</sup></b>	0.04 (0.09)	-0.06 (0.08)	<0.0001	0.726	0.622
<b>FEV1</b>	-0.16 (0.10)	<b>-0.17 (0.08)<sup>c</sup></b>	0.08 (0.07)	0.01 (0.08)	<b>0.23 (0.08)<sup>a</sup></b>	<0.0001	0.619	0.514
<b>FEV1/FVC</b>	<b>-0.04 (0.02)<sup>b</sup></b>	<b>-0.03 (0.01)<sup>b</sup></b>	<b>-0.07 (0.01)<sup>b</sup></b>	-0.02 (0.01)	<b>0.09 (0.01)<sup>b</sup></b>	<0.0001	0.199	0.049
<b>DLCO</b>	<b>-2.23 (0.85)<sup>a</sup></b>	<b>-1.65 (0.65)<sup>b</sup></b>	<b>1.40 (0.62)<sup>c</sup></b>	0.50 (0.70)	-0.04 (0.68)	<0.0001	0.636	0.541

543 <sup>a</sup> P-value <0.001; <sup>b</sup> P-value<0.025; <sup>c</sup> P-value<0.035. <sup>d</sup>Each linear regression model  
 544 included all five radiomic features and was additionally adjusted for age, gender,  
 545 race/ethnicity, BMI and height. Bolded cells are statistically significant (p-values in the  
 546 footnote). GLCM Gaussian is the sum of the GLCM with a Gaussian weight applied.  
 547 GLCM-Inv Gaussian-E is the sum of the GLCM for the inverse Gaussian weighting  
 548 scheme. GLCM Sum Energy is the sum of the squared values in the GLCM and a  
 549 measure of uniformity. GLCM Min is the minimum of the GLCM. P-value is for the partial  
 550 F-test of significance of any of the five radiomic measures.

551

552

553 **Table 5: Holistic interpretation of radiomic clusters in terms of VAS, PFT, and**  
 554 **PRO measures.**

Cluster #	Cluster Description	Directional changes in characteristics	Severe Disease Features <sup>a</sup>
1	Low severity with less LN, less PA and AD and limited shortness of breath (PRO)	Oberstein Score↓↓ Scadding stage 1,2 FEV1, FVC, DLCO↑ LN↓ vs. Cluster 3,4 SOBQ↓ vs. Cluster 4 Age↓ & Female↑	
2	Low severity with more LN, smaller increases in PA and AD and limited PFT and shortness of breath	Oberstein Score↓ Scadding stage 1,2 FEV1, FVC, DLCO↑ LN↑ vs. Cluster 1 SOBQ↓ vs. Cluster 4 Age →, Balanced Sex	
3	Severe obstructive, fibrotic presentation with significant PA, AD, and decreased PFT	Oberstein Score↑↑ vs. 1,2↓ 4 Scadding stage 2,4 FEV1/FVC↓↓ (Obstruction↑), PFT↓ LN → vs. 2 & 4 Age →, Female↑	
4	Severe PA and AD with significant fibrosis; low PFT and increased shortness of breath and fatigue.	Oberstein Score↑↑ Scadding stage 4 FEV1, FVC, DLCO↓↓ LN → vs. 2 & 3 SOBQ, Fatigue↑ Age →, Balanced Sex	

555 <sup>a</sup> No fill represents similar to least impairment observed. Lined shading represents moderate  
 556 impairment or ~25-50% prevalence for Scadding stage. Dark shading represents similar to  
 557 worst impairment observed or ~50% prevalence for Scadding stage.

558

## Figure Legends

**Figure 1:** Heat map of the correlation between different radiomic measures for the entire population.

**Figure 2:** Radiomic cluster differences in average PFT values (columns) from regression models with adjustment for demographics (top row), then additionally adjusted for either Scadding stage or Oberstein score (middle two rows), then adjusted for both Scadding stage and Oberstein score (bottom row). The significance of the cluster differences from cluster 1 are in green ( $p>0.05$ ) and blue ( $p<0.05$ ). The bottom text in each panel is the overall p-value for the association between clustering and PFT outcome along with the  $R^2$ .





**Figure 3:** Radiomic cluster differences in average PRO values (columns) from regression models with adjustment for demographics (top row), then additionally adjusted for either Scadding stage or Oberstein score (middle two rows), then adjusted for both Scadding stage and Oberstein score (bottom row). The significance of the cluster differences from cluster 1 are in green ( $p>0.05$ ) and blue ( $p<0.05$ ). The bottom text in each panel is the overall p-value for the association between clustering and PFT outcome along with the  $R^2$ .


**Figure 4:** CT images in axial orientation for three patients with minimum, median, and maximum values for GLCM Gaussian (left column), the GLCM Inverse Gaussian, and the kurtosis.


**Figure 5:** Separation of Oberstein score and Scadding based kurtosis (y-axis) and GLCM-Min (x-axis) two of the five most important radiomic variables in defining clusters. Colors represent the Oberstein score and Scadding stage.



**Color Key  
and Histogram**







Significance ● FALSE ● TRUE

Max

Median

Min

Inv\_Gauss\_e

Kurtosis

Min

